Sonic Holdco, Inc.
Amendment No. 2 to the S-4 registers shares for a two-step merger: Caldera Merger Sub merges into Caldera, then Synlogic Merger Sub merges into Synlogic, both becoming wholly owned subsidiaries of Sonic Holdco (to be renamed Caldera Therapeutics). Caldera is valued at $500.0 million and Synlogic at $18.0 million (assuming $6.0 million net cash). A concurrent financing of approximately $278.0 million will close alongside the mergers. Post-closing ownership is expected to be ~62.8% Caldera pre-merger holders, ~34.9% financing investors, and ~2.3% Synlogic holders on a fully diluted basis.
- Caldera is valued at $500.0 million; Synlogic at $18.0 million assuming $6.0 million net cash.
- Concurrent financing of approximately $278.0 million closes conditioned on merger closing conditions.
- Post-closing ownership: ~62.8% Caldera holders, ~34.9% financing investors, ~2.3% Synlogic holders.
- Synlogic valuation adjusts dollar-for-dollar for net cash above/below $6.0 million, floored at $8.0 million.
- Support agreements cover ~72.6% of Caldera stock and ~50.9% of Synlogic stock.
Price data unavailable.
Synlogic stockholders are diluted to roughly 2.3% of the combined company while Caldera holders and financing investors take ~97.7%, making this effectively a Caldera IPO through Synlogic's shell.
This is a reverse-merger structure where a private biotech (Caldera) gains public listing through a smaller public shell (Synlogic), a common path for private drug developers to access public markets.
Listing on NYSE American is a closing condition and can be waived without re-solicitation, so Synlogic stockholders vote without certainty on listing. Synlogic's valuation can fall to an $8.0 million floor if net cash is negative.